Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor.

Area of Science:

• Cellular immunotherapy
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows promise for treating various diseases.
• Traditional CAR-T cell manufacturing is complex, costly, and prone to contamination.
• Automated systems offer a solution for scalable and safer cell therapy production.

Purpose of the Study:

• To describe the T cell transduction (TCT) process for CAR-T cell manufacturing using the CliniMACS Prodigy automated system.
• To demonstrate the feasibility and advantages of semi-automated CAR-T cell production.
• To provide a guide for cGMP-compliant manufacturing and regulatory submissions.

Main Methods:

• Utilized the CliniMACS Prodigy for semi-automated CAR-T cell manufacturing.
• Employed the TCT process including T cell enrichment, activation, transduction, expansion, and harvest.
• Customized the process using the Activity Matrix functionality.
• Ensured compliance with current Good Manufacturing Practice (cGMP).

Main Results:

• Demonstrated the feasibility of clinical-scale CAR-T cell manufacturing using the automated system.
• Highlighted reduced human involvement, leading to time savings, decreased variability, and fewer errors.
• Detailed the steps for cGMP-compliant production and discussed release testing requirements.

Conclusions:

• The CliniMACS Prodigy facilitates efficient, scalable, and safer CAR-T cell manufacturing.
• Semi-automated processing minimizes risks associated with traditional methods.
• This approach supports clinical applications, exemplified by an ongoing trial in pediatric B-cell malignancies.